Projects per year
Abstract
Objectives: We aimed to show that prolonged ETO treatment could unintendedly confer fluoroquinolone antibiotic resistance to P. aeruginosa, and evaluate the effect of tumor-associated P. aeruginosa on tumor progression.
Methods: We employed experimental evolution assay to treat P. aeruginosa with prolonged ETO exposure, evaluated the ciprofloxacin resistance, and elucidated the gene mutations by DNA sequencing. We also established a lung tumor-P. aeruginosa bacterial model to study the role of ETO-evolved intra-tumoral bacteria in tumor progression using immunostaining and confocal microscopy.
Results: ETO could generate oxidative stress and lead to gene mutations in P. aeruginosa, especially the gyrase (gyrA) gene, resulting in acquired fluoroquinolone resistance. We further demonstrated using a microfluidic-based lung tumor-P. aeruginosa coculture model that bacteria can evolve ciprofloxacin (CIP) resistance in a tumor microenvironment. Moreover, ETO-induced CIP-resistant (EICR) mutants could form multicellular biofilms which protected tumor cells from ETO killing and enabled tumor progression.
Conclusion: Overall, our preclinical proof-of-concept provides insights into how anti-cancer chemotherapy could inadvertently allow tumor-associated bacteria to acquire antibiotic resistance mutations and shed new light on the development of novel anti-cancer treatments based on anti-bacterial strategies.
© 2023 The Authors. Published by Elsevier B.V. on behalf of Cairo University.
| Original language | English |
|---|---|
| Pages (from-to) | 33-44 |
| Journal | Journal of Advanced Research |
| Volume | 55 |
| Online published | 21 Feb 2023 |
| DOIs | |
| Publication status | Published - Jan 2024 |
Funding
The City University of Hong Kong (9610430, 7005208, 7005464, 7020002, 9667220); Hong Kong Center for Cerebro-Cardiovascular Health Engineering (COCHE); Pneumoconiosis Compensation Fund Board (9211276 and ZJN2); Research Grants Council (RGC 9048206 and 11204317); The Hong Kong Polytechnic University, Department of Applied Biology and Chemical Technology Startup Grant (BE2B), Departmental General Research Fund (UALB), One-line account (ZVVV), Environmental and Conservation Fund (ECF48/2019 and ECF-84/2021), Health and Medical Research Fund (HMRF-201903032), State Key Laboratory of Chemical Biology and Drug Discovery Fund (1-BBX8); and the Hetao ShenzhenHong Kong Science and Technology Innovation Cooperation Zone Shenzhen Park Project (HZQB-KCZYZ-2021017).
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Publisher's Copyright Statement
- This full text is made available under CC-BY-NC-ND 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/
RGC Funding Information
- RGC-funded
Fingerprint
Dive into the research topics of 'Oxidative stress induced by Etoposide anti-cancer chemotherapy drives the emergence of tumor-associated bacteria resistance to fluoroquinolones'. Together they form a unique fingerprint.Projects
- 3 Finished
-
ECS: Microfluidic Inflammatory Tumor Model for Drug Discovery in Patients with Systemic Infection
KHOO, B. L. (Principal Investigator / Project Coordinator)
1/01/22 → 5/06/26
Project: Research
-
HKgovt: Enrichment of Epithelial Mesothelioma Cell Clusters for Early Detection and Routine Monitoring of Patients Using Liquid Biopsy
KHOO, B. L. (Principal Investigator / Project Coordinator) & SUN, D. (Co-Principal Investigator)
1/08/21 → 28/02/25
Project: Research
-
GRF: An Microfluidic Cell Isolation and Biosening Platform for Cytokine Profiling of Individual Immune Cell Types
LAM, H. W. R. (Principal Investigator / Project Coordinator)
1/09/17 → 28/02/22
Project: Research
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver